Barry. I'm start headwinds our with excited the share truly despite ZYNRELEF a marketplace. to We're significant you, in fast quarter commercial results. Thank third off to
with Thus $X.X ABC, distribution accounts. stocking ordering full-line far, start already key in ensure finish our ZYNRELEF and the start the on centers I'll Cargo, have sold distribution established & access reordered. of is our of Oncology ZYNRELEF the launch an McKesson Care X XX% presentation, to delivery off quarter update with of my million. of We've product a and a with utilizing DCs commercial wholesalers, for a launch metrics sales that number stocking During strong ZYNRELEF on and nationwide broad We're of we're Morris channel initial rapid making with Dickson. net results. first progress to these in have XX
in In XX slide stocking distributors hospital an May far, the have or of ZYNRELEF centers, sold utilizing Thus Slide specialty these supply XX to distribution number the we surgical DCs launches. ASC. reordered is successful conference XX% addition, of approval we're call updated had product. ZYNRELEF during regarding and FDA seven version our centers ambulatory shared
added full five the for we've transparency, ANJESO. see, of you'll their one In first included only quarter first As sales. quarters month
X-quarter net is quarter to feel have ZYNRELEF total highlights of Slide that those addition, and sales of the that believe EXPAREL In added number like rapid product excellent we're eight will access. making continue We formulary we exceed start ZYNRELEF off sales. the over progress the ZYNRELEF period. first to with net an initial product
impact October, of The approvals. COVID-XX end of we be have the continued XXX not formulary should of underestimated. As
that without P&T would of additional committee confident formularies already been the to COVID-XX are have added postponing impact ZYNRELEF decisions. We
P&T of committees decisions However, adding making formulary. in are P&T accounts hospital ZYNRELEF to those over actually XX%
label on believe NDA usage greater usage recently of certainly over that are end to filed time year. the procedures. access committee will hospitals additional drive indicated those of P&T the to have ZYNRELEF a of supplemental with scheduled review significant XX% for We the proved ZYNRELEF are and a the be formulary critical in our also these hospitals for with restrictions Importantly, impact will XXX The XXXX of our formulary with before remainder unrestricted broader indications expected approvals ZYNRELEF.
COVID monitor committee closely P&T of to impact on continue potential of timing the will schedules. the We
Fortunately, the formulary P&T In months medical accounts mind number also hospital on to have beginning. committee just pharmacy been schedules, win executive it's approval establishment the the hospitals is step Order in to require launch, or many It's a usage when Symphony and the of number then have unique benchmarks ordering experienced for that typically in Health CPOE first important prior of data. an with a stocking Slide to keep XX important market, we a days. but delays P&T based and sign-off, Computerized in Physician delays process, the XX patients. during X of Entry, nine committee
X when XXX unique traction significant launch indication ZYNRELEF believe label favorably with EXPAREL accounts. a broad this in We COVID EXPAREL results. impact the very first months gaining the of April in and with no with XXXX launched to are of their launch ordering We compares to
nonopioid [indiscernible] the COVID-XX XX have the launched analgesic, of past ZYNRELEF's X next over ZYNRELEF, during the closest is months, Xerocole unique number greater era. accounts times competitor. than ordering and During X
of addition, reordering the four greatest during had months, In XX% analysis. the in X the reorder products this first accounts ZYNRELEF benchmark percentage of
in XX% coverage far relief grow gain satisfied, momentum results accounts the we'll XXXX, price, great strong, of reimbursement of formulary-approved quarter. care growth received effective reimbursing the tremendous impact acquisition expect pass-through New in rate customers and We're on still October remainder without the formulary payment both cases, the meaningful Until This also January setting have While the the across accounts all X, We separate ZYNRELEF's ASCs which also for pain our and and reimbursement expect ordering seeing in a Outpatient fourth fully in ordering the typical continue unique CMS and ASCs a will CMS application, X-year reimbursement the news. drug front component growth Medicare we're ASC pass-through reviewing favorable We've a in an seen is A are covered than issued cost and fronts unique results is ongoing the more system, separate settings wholesale more have XX, outpatient benefits for coverage Yesterday, some quarter. postoperative average a care million published already commercial prospective accounts where final reimbursed the is of ZYNRELEF in calendar reimbursement the Medicaid surgical our early to separate setting. hospital XX year in XXXX. have we procedures of payers. unprecedented and December is XXXX. initial both rule further some and ZYNRELEF our already gene under We've may of beyond ZYNRELEF in additional very for in specific with bundle approvals CMS payment. lower in in will separate we outpatient on the in through from lives the and setting. reimbursement drug. for be SCO bundle pass-through and obtained of outside surgical period. ZYNRELEF even is reimbursement. patients this CXXXX and at pricing Year. key strategy new think since
year key off strong all of the the remainder for on four with in the of built focused ZYNRELEF, have we building We them priorities base QX.
patients in in is new we'll create first with and are even and trials, initial we've better exciting, and users. saw loyal a services First, experience extremely convert seen continue positive heard we pull-through to than which surgeons. clinical to physicians for both and from The activities, into usage surgeons results formulary-approved including expand accounts those our
fact, used have cases in surgeons have results, we been TKA it In over already several who so ZYNRELEF impressed launch. orthopedic XXX they've with since
Network, unique we'll routinely accounts to focus build Second, at to access at that the IDN, formulary gaining on level Integrated hospital Delivery are more both reordering. continue or
marketplace XX% the the hospital unmet great demonstrates the approval us formulary in confidence gives future. Our for need rating and
and ZYNRELEF financial for hours critical specific surgical employer of process. CMS with first covering has reimbursement non-opioid in superiority another clinical of bupivacaine customers of pain in standard continue the patients. ZYNRELEF reduction. solutions outside in C-code ZYNRELEF to our the this creating FDA in for local bundle is access been reimbursement factor the positive to release step commercial up benefit care issuing the coverage, expand news - XX XX we'll demonstration is to our to to by separate The a Third, with ASCs for up anesthetic, designated only with Yesterday's and trials. commercial greater and a payers extended
position excellent expand us an of FDA indications Finally, ZYNRELEF we approves new the remain base confident put described once strong our by usage previously that to were will business Barry. in label the
review gears like franchise. I'd Now the shift for our Oncology results third and Care quarter to
another quarter the decreasing X% with cancer products over sales represented the screening was which We have franchise increase quarter performance a CIMB million, some third headwinds in for the and of COVID, starts. The third new of did $XX.X the solid with year. impact prior net patient
generic cheaper towards and Secondly, CMS' model support community other oncology move biosimilar care products. contracts and oncology value-based practices
maintaining Lastly, is the were beginning competitive Nevertheless, in recovery products or growth segment This XXXX. practices both belief believe to high sales based with are aggressive pricing. poised [indiscernible] oncology we cost in net value factors. key that two on for clinic
generic makes CINVANTI's quarter, which profit $XX.XX First, decreased and has XXXX. value reimbursement attractive much for fast from ASP in more down in to the 'XX, practices prior QX XX% oncology
a of we result create both patients, believe starts as used the treatment, both that backlog for since will MEC COVID, of in and oncology of patient Second, for there's opportunities new as products. reenter be the majority growth a new of patients system HEC can regimens our and these products
$XX During million. to be the range expect sales product we the XXXX, of to $XX CIMB of quarter in net million fourth
job sales XXXX, team dominated done stabilizing net generic competition. by our During excellent an markets our CINV has and of portfolio
see we the program refresh and in generally started net implemented growing in process stabilized CINVANTI graph, following SUSTOL sales XXXX. we've can of you the As the
believe closer CINV we On moderate for are poised take As mentioned slide, look number at on that growth side XXXX. a previous SUSTOL. products we in the XX,
reimbursement we fourth in reset XXXX, During growth to takes in all continued of process growth This in following expect refresh the XXXX, SUSTOL program and removed implement to ASP discounting for we returned the order SUSTOL the and from five product. quarters XXXX. quarter we the to
Barry. to oncology brief review turn of call back the that I'll the now Following over franchise,
